Publications

NPJ breast cancer

Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance.

06-05-2022

Nature communications

Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion.

09-09-2020

Nature communications

Genomic data integration by WON-PARAFAC identifies interpretable factors for predicting drug-sensitivity in vivo.

06-11-2019

Nature

Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis.

01-08-2019

The Journal of clinical investigation

Low tristetraprolin expression activates phenotypic plasticity and primes transition to lethal prostate cancer in mice.

19-11-2024

Nucleic acids research

Chromatin context-dependent effects of epigenetic drugs on CRISPR-Cas9 editing.

27-08-2024

The Journal of clinical investigation

Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer.

13-08-2024

Nature genetics

Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer.

01-08-2024

Journal of experimental & clinical cancer research : CR

Emerging frontiers in androgen receptor research for prostate Cancer: insights from the 2nd international androgen receptor Symposium.

17-07-2024

BMC medical genomics

Co-expression in tissue-specific gene networks links genes in cancer-susceptibility loci to known somatic driver genes.

15-07-2024

FEBS letters

Nuclear receptor Nur77 and Yin-Yang 1 synergistically increase mitochondrial abundance and activity in macrophages.

01-07-2024

Cancer discovery

Cancer Core Europe: Leveraging Institutional Synergies to Advance Oncology Research and Care Globally.

01-07-2024

European journal of cancer (Oxford, England : 1990)

Oncological outcomes after a pathological complete response following total neoadjuvant therapy or chemoradiotherapy for high-risk locally advanced rectal cancer in the RAPIDO trial.

01-06-2024

Genome research

Estrogen receptor 1 chromatin profiling in human breast tumors reveals high inter-patient heterogeneity with enrichment of risk SNPs and enhancer activity at most-conserved regions.

15-05-2024

Clinical genitourinary cancer

Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant Prostate Cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy.

01-04-2024

NPJ systems biology and applications

Agent-based modeling of the prostate tumor microenvironment uncovers spatial tumor growth constraints and immunomodulatory properties.

21-02-2024

Cancers

It Takes Two to Tango: The Interplay between Prostate Cancer and Its Microenvironment from an Epigenetic Perspective.

10-01-2024

Molecular oncology

Proteomics on malignant pleural effusions reveals ERα loss in metastatic breast cancer associates with SGK1-NDRG1 deregulation.

01-01-2024

EMBO molecular medicine

Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity.

07-12-2023

Life science alliance

TRIM25 targets p300 for degradation.

01-12-2023

ESMO open

Corrigendum to "Authors' reply-Does the RAPIDO trial suggest a benefit of post-operative chemotherapy after preoperative chemoradiation in rectal cancer? No, it does not": [ESMO Open 8 (2023) 101645].

01-12-2023

Nucleic acids research

Compartmentalization of androgen receptors at endogenous genes in living cells.

10-11-2023

Cancer discovery

Transposable Elements Are Co-opted as Oncogenic Regulatory Elements by Lineage-Specific Transcription Factors in Prostate Cancer.

01-11-2023

European urology

Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor-driven Programs.

01-11-2023

Cell reports

Perturbations in 3D genome organization can promote acquired drug resistance.

31-10-2023

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Inhibiting the Glucocorticoid Receptor to Enhance Chemotherapy Response.

20-10-2023

Nucleic acids research

PAXIP1 and STAG2 converge to maintain 3D genome architecture and facilitate promoter/enhancer contacts to enable stress hormone-dependent transcription.

13-10-2023

ESMO open

Authors' reply-Does the RAPIDO trial suggest a benefit of post-operative chemotherapy after preoperative chemoradiation in rectal cancer? No, it does not.

01-10-2023

Cellular and molecular life sciences : CMLS

Crosstalk between glucocorticoid and mineralocorticoid receptors boosts glucocorticoid-induced killing of multiple myeloma cells.

14-08-2023

Cancer research communications

Exploring the Onset and Progression of Prostate Cancer through a Multicellular Agent-based Model.

01-08-2023

Virchows Archiv : an international journal of pathology

Reliability of whole mount radical prostatectomy histopathology as the ground truth for artificial intelligence assisted prostate imaging.

01-08-2023

Bioinformatics advances

snHiC: a complete and simplified snakemake pipeline for grouped Hi-C data analysis.

03-07-2023

Cancers

Radiogenomics Analysis Linking Multiparametric MRI and Transcriptomics in Prostate Cancer.

06-06-2023

Annals of oncology : official journal of the European Society for Medical Oncology

Authors' reply-A sensitivity analysis of the RAPIDO clinical trial.

01-04-2023

ESMO open

The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancer-results from the RAPIDO trial.

01-04-2023

Cancers

The Tumor Coagulome as a Transcriptional Target and a Potential Effector of Glucocorticoids in Human Cancers.

28-02-2023

Proceedings of the National Academy of Sciences of the United States of America

Mammalian life depends on two distinct pathways of DNA damage tolerance.

24-01-2023

Nature communications

Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential.

30-11-2022

Cancer research

The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.

02-11-2022

Nature communications

MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling.

02-11-2022

Endocrinology

Homing in on a Moving Target: Androgen Receptor Cistromic Plasticity in Prostate Cancer.

11-10-2022

Nucleic acids research

Double-strand break toxicity is chromatin context independent.

23-09-2022

Advances in experimental medicine and biology

Prostate Cancer Epigenetic Plasticity and Enhancer Heterogeneity: Molecular Causes, Consequences and Clinical Implications.

16-09-2022

Cancer discovery

Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.

02-09-2022

Nature genetics

Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation.

01-09-2022

Nucleic acids research

HDAC1 and PRC2 mediate combinatorial control in SPI1/PU.1-dependent gene repression in murine erythroleukaemia.

12-08-2022

Nature communications

Ribosome impairment regulates intestinal stem cell identity via ZAKɑ activation.

02-08-2022

Clinical epigenetics

Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancer.

04-05-2022

EMBO reports

Unexpected gene activation following CRISPR-Cas9-mediated genome editing.

03-02-2022

Prostate cancer and prostatic diseases

Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223.

01-02-2022

Comprehensive characterization of pre- and post-treatment samples of breast cancer reveal potential mechanisms of chemotherapy resistance.

Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion.

Genomic data integration by WON-PARAFAC identifies interpretable factors for predicting drug-sensitivity in vivo.

Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis.

Low tristetraprolin expression activates phenotypic plasticity and primes transition to lethal prostate cancer in mice.

Chromatin context-dependent effects of epigenetic drugs on CRISPR-Cas9 editing.

Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer.

Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer.

Emerging frontiers in androgen receptor research for prostate Cancer: insights from the 2nd international androgen receptor Symposium.

Co-expression in tissue-specific gene networks links genes in cancer-susceptibility loci to known somatic driver genes.

Nuclear receptor Nur77 and Yin-Yang 1 synergistically increase mitochondrial abundance and activity in macrophages.

Cancer Core Europe: Leveraging Institutional Synergies to Advance Oncology Research and Care Globally.

Oncological outcomes after a pathological complete response following total neoadjuvant therapy or chemoradiotherapy for high-risk locally advanced rectal cancer in the RAPIDO trial.

Estrogen receptor 1 chromatin profiling in human breast tumors reveals high inter-patient heterogeneity with enrichment of risk SNPs and enhancer activity at most-conserved regions.

Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant Prostate Cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy.

Agent-based modeling of the prostate tumor microenvironment uncovers spatial tumor growth constraints and immunomodulatory properties.

It Takes Two to Tango: The Interplay between Prostate Cancer and Its Microenvironment from an Epigenetic Perspective.

Proteomics on malignant pleural effusions reveals ERα loss in metastatic breast cancer associates with SGK1-NDRG1 deregulation.

Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity.

TRIM25 targets p300 for degradation.

Corrigendum to "Authors' reply-Does the RAPIDO trial suggest a benefit of post-operative chemotherapy after preoperative chemoradiation in rectal cancer? No, it does not": [ESMO Open 8 (2023) 101645].

Compartmentalization of androgen receptors at endogenous genes in living cells.

Transposable Elements Are Co-opted as Oncogenic Regulatory Elements by Lineage-Specific Transcription Factors in Prostate Cancer.

Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor-driven Programs.

Perturbations in 3D genome organization can promote acquired drug resistance.

Inhibiting the Glucocorticoid Receptor to Enhance Chemotherapy Response.

PAXIP1 and STAG2 converge to maintain 3D genome architecture and facilitate promoter/enhancer contacts to enable stress hormone-dependent transcription.

Authors' reply-Does the RAPIDO trial suggest a benefit of post-operative chemotherapy after preoperative chemoradiation in rectal cancer? No, it does not.

Crosstalk between glucocorticoid and mineralocorticoid receptors boosts glucocorticoid-induced killing of multiple myeloma cells.

Exploring the Onset and Progression of Prostate Cancer through a Multicellular Agent-based Model.

Reliability of whole mount radical prostatectomy histopathology as the ground truth for artificial intelligence assisted prostate imaging.

snHiC: a complete and simplified snakemake pipeline for grouped Hi-C data analysis.

Radiogenomics Analysis Linking Multiparametric MRI and Transcriptomics in Prostate Cancer.

Authors' reply-A sensitivity analysis of the RAPIDO clinical trial.

The value of post-operative chemotherapy after chemoradiotherapy in patients with high-risk locally advanced rectal cancer-results from the RAPIDO trial.

The Tumor Coagulome as a Transcriptional Target and a Potential Effector of Glucocorticoids in Human Cancers.

Mammalian life depends on two distinct pathways of DNA damage tolerance.

Extensive androgen receptor enhancer heterogeneity in primary prostate cancers underlies transcriptional diversity and metastatic potential.

The 5-Hydroxymethylcytosine Landscape of Prostate Cancer.

MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling.

Homing in on a Moving Target: Androgen Receptor Cistromic Plasticity in Prostate Cancer.

Double-strand break toxicity is chromatin context independent.

Prostate Cancer Epigenetic Plasticity and Enhancer Heterogeneity: Molecular Causes, Consequences and Clinical Implications.

Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence.

Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation.

HDAC1 and PRC2 mediate combinatorial control in SPI1/PU.1-dependent gene repression in murine erythroleukaemia.

Ribosome impairment regulates intestinal stem cell identity via ZAKɑ activation.

Androgen receptor reprogramming demarcates prognostic, context-dependent gene sets in primary and metastatic prostate cancer.

Unexpected gene activation following CRISPR-Cas9-mediated genome editing.

Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223.

This site uses cookies